NCT01207908View on ClinicalTrials.gov

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

June 30, 2013

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

IGF-1

IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

collaborator

Charley's Fund

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER